My expectation is that it will be a slow burn without significant price sensitive news for 3-6 months. the catalysts may be another meeting with the FDA/EMA which is unscheduled to investors knowledge (ie. no date known). The pharmacokinetics study and phase 3 designs more likely 1H CY 2021. With such a tightly held register I would expect that if positive release from any of the above then it will re-rate sharply IMO. Circa opthea though maybe not to same 400% extent. My thoughts only.
Add to My Watchlist
What is My Watchlist?
